Inactive Instrument

Other languages Bausch Health Companies Inc Toronto S.E.

Equities

CA91911K1021

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Bausch Health in 'Stronger Position' for Bausch + Lomb Distribution, RBC Says	Apr. 23
RBC Previews Bausch Health's Q1, Trims Target to US$11	Apr. 23
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says	Apr. 12
Bausch wins US appeal to block Alvogen generic of diarrhea drug	Apr. 11
Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan	Apr. 11
TSX ends flat as gold stocks drop, mood cautious ahead of rate decision	Apr. 08
RBC Raises Bausch Health Target to US$12, Maintains Sector Perform, on Upcoming Xifaxan Litigation Ruling	Apr. 05
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults	Apr. 03
Toronto healthcare stocks rise in flat market, Canada Goose slides	Mar. 26
Insider - Milliardäre sammelten Geld für Trumps Sicherheitsleistung	Mar. 26
Billionaires sought to help fund Trump bond in civil fraud case, sources say	Mar. 25
Bausch Health's Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of Relistor	Mar. 06
Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma	Mar. 06
RBC Raises Bausch Health Target to US$9, After Q4 And 2024 Guidance	Feb. 23
TSX closes at 22-month high powered by tech rally	Feb. 22
Bausch + Lomb's Likely to Face Market-Related Risks From Spin, RBC Says	Feb. 22
Bausch Health's Q4 Loss Narrows, Revenue Increases; Issues 2024 Revenue Outlook; Shares Gain Pre-Bell	Feb. 22
Bausch Health Reports Q4 2023 Adjusted Earnings of US$406 Million; Revenue of US$2.4 Billion	Feb. 22
Bausch Health Companies Inc. Provides Earnings Guidance for the Year 2024	Feb. 22
Bausch Health Companies Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Bausch Health Companies Inc Toronto S.E.

Equities

CA91911K1021

Other languages

Filters